Results 231 to 240 of about 1,414,184 (301)

Civil society is essential public health infrastructure that Europe cannot afford to lose. [PDF]

Eur J Public Health
Sokolović M, Lauriola P, Albreht T, Marchandise C.   +3 more
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

When the therapist hallucinates: AI, psychedelics, and the risks of unsupervised digital mental health care. [PDF]

Digit Health
MacIntyre MR.
europepmc   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Comment on Leivaditis et al. Artificial Intelligence in Cardiac Surgery: Transforming Outcomes and Shaping the Future. <i>Clin. Pract.</i> 2025, <i>15</i>, 17. [PDF]

Clin Pract
Haq HU, Khan MAH.
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Abuse from the First Night: The Dark Reality of Intimate Partner Violence in Child Marriages. [PDF]

Iran J Public Health
Aghakhani N, Ewalds-Kvist BM, Aghakhani S, Alishahihesar B, Abolfathpour P.   +4 more
europepmc   +1 more source

Empowering citizens to spontaneously report suspected adverse drug reaction: Systematic literature review of interventions and their impact

British Journal of Clinical Pharmacology, EarlyView.
This systematic literature review aimed to identify and characterize existing interventions designed to empower citizens to spontaneously report adverse drug reactions (ADRs) and to determine which interventions have been shown to be the most effective internationally. The research question was structured using the PICO framework.
Margarida Perdigão, Ana Margarida Advinha, Manuel José Lopes, Sofia de Oliveira Martins   +3 more
wiley   +1 more source

Help, near and far: a systematic review of post-COVID digital mental health solutions for domestic violence victims. [PDF]

Front Public Health
Yu P, Zhu P, Kudiza A, Kaburu FM, Intizar M, Tong C, Zhang R, Jiang J, Yu X, Kuang Q, Chen R, da Veiga CP, Xiang YT, Su Z.   +13 more
europepmc   +1 more source